280TiPGOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. (25th November 2018) - Tewari, K S; Vergote, I; Oaknin, A; Alvarez, E; Gaillard, S; Lheureux, S; Rischin, D; Santin, A D; Feng, M; Mathias, M; Fury, M; Lowy, I; et al.